News broke Tuesday that after only a few hours of deliberation, a jury sided with Apple in its defense against a class action lawsuit accusing the company of violated antitrust law through its business practices regarding the iPod; a decision now rests in the hands of a jury.
Closing arguments were held Monday in the case that centered on the purpose of software updates for Apple iPods.
The more than 10-year-old legal battle was launched by a group of iPod purchasers who claim that Apple’s iPod updates were intended to prevent customers from successfully playing songs on the devices that were not downloaded straight from iTunes or a CD. The plaintiffs sought $350 million in damages, an amount that could have been tripled.
But Apple claimed there is “overwhelming” evidence that the iPod software updates were meant to improve product function and consumer experience. “We now have a plaintiff and a case asking you to hold Apple liable for innovating,” a lawyer for the technology conglomerate said during closing arguments.
The eight-person jury reportedly unanimously sided with Apple in deciding that the softwware updates were solely for the purpose of performance improvements.
Plaintiffs had struggled to push forward with their suit; after a decade, the class almost had to abandon the case when it was found that its two lead plaintiffs did not actually qualify to sue Apple for the claims because they did not purchase an iPod during the time in question by the allegations.
Apple’s motion to have the case dismissed entirely, however, failed, and the class found a last-minute lead plaintiff to save the suit. But with the jury’s findings, plaintiffs reportedly plan to appeal the desicion.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas